Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambien CR Gets FDA Approval; Launch Expected In Mid-September

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.
Advertisement

Related Content

Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Takeda Rozerem Clinical Significance Debated In FDA Review
Sanofi-Aventis Ambien CR Launch Gets Up And Going
Takeda's Rozerem To Launch In September Following FDA Approval
Takeda's Rozerem To Launch In September Following FDA Approval
Takeda’s Sleep Aid Rozerem Could Avoid Controlled Substance Scheduling, Firm Says
Lunesta Has "Encouraging" Debut, Sepracor Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel